JLE

Epileptic Disorders

MENU

One-year clinical experience of perampanel in Spain: a multicentre study of efficacy and tolerability Volume 18, issue 2, June 2016

  • [Biró et al., 2015] Biró A., Stephani U., Tarallo T. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies: first experiences. Neuropediatrics. 2015;46:110-115. 2
  • [Coyle et al., 2014] Coyle H., Clough P., Cooper P., Mohanraj R. Clinical experience with perampanel: focus on psychiatric adverse effects. Epilepsy Behav. 2014;41:193-196.
  • [Ettinger et al., 2015] Ettinger A.B., LoPresti A., Yang H. Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA. Epilepsia. 2015;56:1252-1263. 8
  • [European Medicines Agency, 2015] European Medicines Agency. Fycompa summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/human/002434/WC500130815.pdf [Accessed August 7, 2015].
  • [French et al., 2012] French J.A., Krauss G.L., Biton V. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology. 2012;79:589-596.
  • [French et al., 2013] French J.A., Krauss G.L., Steinhoff B.J. Evaluation of adjunctive perampanel in patients with refractory partial onset seizures: results of randomized global phase III study 305. Epilepsia. 2013;54:117-125. 1
  • [French et al., 2015] French J.A., Krauss G.L., Wechsler R.T. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy: a randomized trial. Neurology. 2015;85:950-957. 11
  • [Gidal et al., 2015] Gidal B.A., Laurenza A., Husein Z. Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy. Neurology. 2015;84:1972-1980. 19
  • [Hsu et al., 2013] Hsu W.W., Sing C.W., He Y., Worsley A.J., Wong I.C.K., Chan E.W. Systematic review and meta-analysis of the efficacy and safety of perampanel in the treatment of partial onset epilepsy. CNS Drugs. 2013;27:817-827. 10
  • [Kramer et al., 2014] Kramer L.D., Satlin A., Krauss G.L. Perampanel for adjunctive treatment of partial-onset seizures: a pooled dose-response analysis of phase III studies. Epilepsia. 2014;55:423-431. 8
  • [Krauss et al., 2012] Krauss G.L., Serratosa J.M., Villanueva V. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology. 2012;79:1408-1415. 6
  • [Krauss et al., 2014] Krauss G.L., Perucca E., Ben-Menachem E. Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307. Epilepsia. 2014;55:1058-1068.
  • [Kwan et al., 2015] Kwan P., Brodie M.J., Laurenza A. Analysis of pooled phase III trials of adjunctive perampanel for epilepsy: impact of mechanism of action and pharmacokinetics on clinical outcomes. Epilepsy Res. 2015;117:117-124.
  • [Leppik et al., 2015] Leppik I.E., Robert T., Wechsler R.T. Efficacy and safety of perampanel in the subgroup of elderly patients included in the phase III epilepsy clinical trials. Epilepsy Res. 2015;110:216-220.
  • [Montouris et al., 2015] Montouris G., Yang H., Williams B., Zhou S., Laurenza A., Fain R. Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel. Epilepsy Res. 2015;114:131-140.
  • [Rektor, 2013] Rektor I. Perampanel, a novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistance partial-onset seizures. Expert Opin Pharmacother. 2013;14:225-235. 2
  • [Rogawski and Hanada, 2013] Rogawski M.A., Hanada T. Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. Acta Neurol Scand Suppl. 2013;197:19-24.
  • [Rosenfeld et al., 2015] Rosenfeld W., Conry J., Lagae L. Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study. Eur J Paediatr Neurol. 2015;19:435-445. 4
  • [Shah et al., 2016] Shah E., Reuber M., Goulding P., Flynn C., Delanty N., Kemp S. Clinical experience with adjunctive perampanel in adult patients with uncontrolled epilepsy: a UK and Ireland multicentre study. Seizure. 2016;34:1-5.
  • [Steinhoff et al., 2013] Steinhoff B.J., Ben-Menachem E., Ryvlin P. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizure: a pooled analysis of three phase III studies. Epilepsia. 2013;54:1481-1489. 8
  • [Steinhoff et al., 2014] Steinhoff B.J., Hamer H., Trinka E. A multicenter survey of clinical experiences with perampanel in real life in Germany and Austria. Epilepsy Res. 2014;108:986-988. 5
  • [Trinka et al., 2016] Trinka E., Steinhoff B.J., Nikanorova M., Brodie M.J. Perampanel for focal epilepsy: insights from early clinical experience. Acta Neurol Scand. 2016;133:160-172. 3
  • [Zaccara et al., 2013] Zaccara G., Giovannelli F., Cincotta M. The adverse event profile of perampanel: meta-analysis of randomized controlled trials. Eur J Neurol. 2013;20:1204-1211. 8